Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-06-17Clinical Trial Update: JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 study of JWCAR239 for B-cell non-Hodgkin lymphoma is not yet recruiting, with indications including diffuse large B-cell lymphoma, f…
-
CLINICAL_TRIALS trial_result · 2025-06-13Clinical Trial Update: Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma [Phase 2]
Phase II trial of venetoclax plus rituximab as initial therapy for older patients with mantle cell lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of selinexor in combination with ibrutinib for relapsed or refractory chronic lymphocytic leukemia and aggressive non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2025-06-06Clinical Trial Update: Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL [Phase 2]
This trial update reports Phase 2 results for a triple regimen of acalabrutinib, lenalidomide, and rituximab in patients with untreated Mant…
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation [Phase 2]
Phase 2 trial comparing three GVHD prophylaxis regimens in nonmyeloablative or reduced-intensity conditioning unrelated donor transplantatio…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating dendritic cell therapy with cryosurgery and pembrolizumab in various Non-Hodgkin lymphoma subtypes, w…
-
CLINICAL_TRIALS trial_result · 2025-05-13Clinical Trial Update: Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma [Phase 2]
Phase 2 trial results evaluating acalabrutinib after blood or marrow transplantation in mantle cell lymphoma; results posted in May 2025.
-
CLINICAL_TRIALS trial_result · 2025-05-13Clinical Trial Update: The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma [EARLY_Phase 1]
Early-phase phase 1 study evaluating the combination of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed/refractory mantle cel…
-
CLINICAL_TRIALS trial_result · 2025-04-27Clinical Trial Update: RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 study evaluating everolimus (RAD001) in relapsed or refractory hematologic malignancies, including leukemia, mantle ce…
-
CLINICAL_TRIALS trial_result · 2025-04-25Clinical Trial Update: Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma [Phase 1]
A Phase 1 trial evaluating the combination of Abexinostat and Ibrutinib in diffuse large B-cell lymphoma and mantle cell lymphoma has comple…
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]
Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …
-
CLINICAL_TRIALS trial_result · 2025-04-20Clinical Trial Update: A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma [Phase 2]
A Phase 2 study evaluating tafasitamab plus lenalidomide in mantle cell lymphoma has been terminated, and results were posted on 2025-04-20.
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
Clinical trial update on a Phase I/II study evaluating the safety of autologous CD20 CAR-T cells in relapsed or refractory B-cell non-Hodgki…
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating the combination of zanubrutinib and rituximab for indolent mantle cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-04-08Clinical Trial Update: Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating a multi-agent regimen of rituximab, bendamustine hydrochloride, and bortezomib, followed by rituximab and lenalid…
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma [Phase 1]
Phase 1 trial evaluating avelumab, utomilumab, rituximab, ibrutinib, and chemotherapy in patients with relapsed or refractory diffuse large …
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies [Phase 1, Phase 2]
Acalabrutinib is being evaluated in Phase 1/2 studies in Chinese adults with relapsed or refractory mantle cell lymphoma and chronic lymphoc…
-
CLINICAL_TRIALS trial_result · 2025-03-11Clinical Trial Update: A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea
A completed non-interventional study in Korea assessing lenalidomide (REVLIMID) for IPSS low- or intermediate-1-risk myelodysplastic syndrom…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease [Phase 2]
Phase 2 trial evaluating an umbilical cord blood transplant regimen with cyclophosphamide, fludarabine, and total-body irradiation for hemat…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning with fludarabine and melphalan plus total body irradiation for haploidentical stem c…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL [Phase 3]
Phase 3 trial comparing R-CHOP plus R-HAD versus R-CHOP followed by maintenance lenalidomide plus rituximab, with an additional maintenance …
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
A completed trial evaluating the relationship between lenalidomide and tumor flare reactions in participants with relapsed or refractory man…
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating ofatumumab with or without bendamustine for mantle cell lymphoma ineligible for autologous stem cell transplant; re…
-
CLINICAL_TRIALS trial_result · 2025-02-26Clinical Trial Update: Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial [NA]
This update notes the completion of the MCL MATCH trial, which investigates signaling pathway dysregulations and in vitro screening with per…
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies [Phase 1, Phase 2]
This completed Phase 1/2 trial evaluates the combination of cirmtuzumab and ibrutinib in patients with B-cell lymphoid malignancies, includi…